We only have this paper's title and publication details.
Read it at the sourceRandomized trial uncovers the impact of antibody development on pegloticase efficacy in refractory chronic gout, suggesting immunogenicity impairs long-term therapeutic success.
NCT00325195. Registered 10 May 2006, NCT01356498. Registered 27 October 2008.
No takes yet. Share an insight, caveat, or question.
Lipsky et al. (2014) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: